Mon panier

APC-Labeled Monoclonal Anti-Human CD14 Antibody, Mouse IgG1 (20F9E3) (0.03% Proclin)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD4-AMY2061-25tests
$100.00
CD4-AMY2061-200tests
$500.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Monoclonal Anti-Human CD14 Antibody, Mouse IgG1 (20F9E3) is a mouse monoclonal antibody recombinantly expressed from HEK293 cells, which provides higher batch consistency and long term security of supply.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    20F9E3

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Human

  • Immunogen

    Purified Human CD14 Protein

  • Conjugate

    APC

    Excitation Wavelength: 640 nm

    Emission Wavelength: 661 nm

  • Specificity

    This product is a specific antibody specifically reacts with CD14 protein.

  • Application

    Flow Cytometry (Evaluation of the expression of CD14 on Human cells).

  • Recommended Dilution

    1:50

  • Isotype Control

    The isotype control is sold separately; please refer to Cat. No. DNP-AFM1 for product information.

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 12 months after reconstitution.
    3. 2-8 °C for 12 months after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-FACS

     CD14 FACS

    Flow cytometric analysis of Human peripheral blood monocytes staining with APC-Labeled Monoclonal Anti-Human CD14 Antibody, Mouse IgG1 (20F9E3) (Cat. No. CD4-AMY2061) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. APC signal was used to evaluate the binding activity (QC tested).​

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Cluster of differentiation 14 (CD14), is a cell surface glycoprotein, and is a is a component of the innate immune system. CD14 is a myelomonocytic differentiation antigen preferentially expressed on monocytes, macrophages, and activated granulocytes. CD14 exists in two forms. Either it is anchored into the membrane by a glycosylphosphatidylinositol tail (mCD14) or it appears in a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa). CD14 acts as a co-receptor (along with the Toll-like receptor TLR 4 and MD-2) for the detection of bacterial lipopolysaccharide (LPS). CD14 can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). CD14 has been proposed to be involved in various biological processes, including transportation of other lipids, cell-cell interaction during different immune responses, as well as recognition of apoptotic cells. Although LPS is considered its main ligand, CD14 also recognizes other pathogen-associated molecular patterns. CD14+ cells are monocytes that can differentiate into a host of different cells. CD14 has been shown to interact with Lipopolysaccharide-binding protein.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Monocyte differentiation antigen CD14

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    3 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte